

CORRECTION

Open Access



Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

Bo Yu¹ and Delong Liu^{2,3*}

Correction to: J Hematol Oncol (2019) 12:94

<https://doi.org/10.1186/s13045-019-0786-6>

Drs Meghdad Abdollahpour-Alitappeh & Majid Lotfinia and their colleagues, Sajad Yaghoubi, Aliyar Pirouzi, Mohammad Hossein Karimi, Tohid Gharibi, Motahare Mahi-Birjand, Shiva Mohammadi, Koushan Sineh Sepehr, Nader Bagheri from Iran have written to the *Journal of Hematology & Oncology* regarding the article on antibody-drug conjugates (ADC) [1]. They raised the question that moxetumomab pasudotox (MS) is not an ADC. We appreciate their attention to the publication. We wish to make correction and clarification on this question. First of all, they are correct in pointing out that MS is not a conventional ADC which is usually an antibody conjugated to a cytotoxic chemical payload [2]. MS is an antibody conjugated to a cytotoxic bacterial toxin payload, which is commonly referred to as immunotoxin [3]. Considering the scope and topic of the contents we summarized on the clinical use of ADCs for lymphoma and multiple myeloma, we believe it may be better to keep the section in the article, but with the specific correction that MS is not a conventional ADC, rather an antibody-toxin conjugate, an immunotoxin.

Author details

¹Department of Medicine, Lincoln Medical Center, Bronx, NY, USA.

²Department of Oncology, The First affiliated Hospital of Zhengzhou

University, Zhengzhou, China. ³Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, USA.

Published online: 04 June 2020

References

1. Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. *J Hematol Oncol*. 2019;12(1):94.
2. Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadhosseinabadi B, Larki P, Faghfourian B, Sepehr KS, Abbaszadeh-Goudarzi K, Abbaszadeh-Goudarzi G, Johari B, Zali MR, Bagheri N. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. *J Cell Physiol*. 2019;234(5):5628–42.
3. Hassan R, Alewine C, Pastan I. New life for Immunotoxin Cancer therapy. *Clin Cancer Res*. 2016;22(5):1055–8.

The original article can be found online at <https://doi.org/10.1186/s13045-019-0786-6>.

* Correspondence: delong_liu@nymc.edu

²Department of Oncology, The First affiliated Hospital of Zhengzhou University, Zhengzhou, China

³Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.